跳至主要内容
临床试验/KCT0002169
KCT0002169招募中未知

Optimal Treatment Strategy Based on Prognostic Groups for Pediatric de Novo Acute Myeloid Leukemia

The Catholic University of Korea, Seoul St. Mary's Hospital0 个研究点目标入组 350 人开始时间: 待定最近更新:
适应症

试验速览

阶段
未知
状态
招募中
入组人数
350

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
o Limit 至 18(Year)(—)
性别
All

入选标准

  • 1) Patients who were newly diagnosed with de novo AML
  • 2) Patients who had recurrent cytogenetic abnormalities of AML even though the bone marrow blast percent is lower than 20%

排除标准

  • 1) Acute promyelocytic leukemia
  • 2) Down syndrome AML
  • 3) Therapy-related AML
  • 4) AML developed from myelodysplastic syndrome or other marrow failure syndrome
  • 5) Isolated myeloid sarcoma without bone marrow involvement
  • 6) Patients who cannot undergo chemotherapy as scheduled due to serious complications at diagnosis

研究者

相似试验

Optimal Treatment Strategy for Pediatric AM | 临床试验